OCuSOFT® Announces Positive Results from Dry Eye Study with Retaine®

Product available through pharmacies and eye care professionals

RICHMOND, TX (March 3, 2015) – OCuSOFT, Inc. is pleased to announce Clinical Ophthalmology has published the positive results from a clinical investigation of their flagship dry eye product, Retaine^®. The study¹ confirmed previous study results and demonstrated significant effects on both signs and symptoms of dry eye disease following two weeks of dosing.

“Achieving statistically significant improve­ments in both signs and symptoms is extremely challenging, as evidenced by the high number of clinical trials involving therapy for Dry Eye,” said Dr. Marguerite McDonald of Ophthalmic Consultants of Long Island and Clinical Professor of Ophthalmology, NYU School of Medicine, New York, US. “The significant improvements in both signs and symptoms with Retaine^® indicate that it is an effective therapy for dry eye patients. The reduction in central corneal staining is especially important from a clinical perspective, as the central cornea is critical to visual function.”

Retaine^® ophthalmic emulsion (marketed outside the United States as Cationorm^® from Santen Pharmaceutical Co LTD [4536:JP]) is a cationic emulsion that contains mineral oil and targets all three layers of the tear film. In this forty-two patient study following two weeks of dosing, there were significant reductions in corneal fluorescein staining, a hallmark sign of dry eye disease, in the superior (P=0.002), central (P=0.017), corneal sum (P=0.011) and all ocular regions combined (P=0.038). A 40% reduction was observed in mean area breakup. Significant improvements in patient evaluated symptoms including discomfort (P=0.0017), dryness (P<0.001) and grittiness (P=0.0217) provide insight into the improvement in quality of life experienced by these patients.

“We are extremely encouraged by the results of this study and the feedback we have received from both patients and physicians since launching Retaine^®,” said Cynthia Barratt, President/CEO of OCuSOFT, Inc. “Eye care professionals have always been and continue to be core to our business and the adoption of our products into the marketplace. Providing our physician network the ability to sell our products directly to their patients, enables a higher level of service and personalization in treating diseases like Dry Eye.”

Retaine^® is currently available for purchase through eye care professionals nationwide as well as at more than 6,500 Walgreens locations. Additionally, Retaine^® may be ordered through pharmacies and is available for direct purchase by calling (800) 233-5469 or online at www.ocusoft.com.

About OCuSOFT, Inc.

OCuSOFT, Inc. is a privately-held Richmond, TX USA-based ophthalmic research, development and supply company with an established reputation for innovation, particularly in the area of Ocular Surface Disease. Since 1986, OCuSOFT^® has served the ophthalmic industry with a unique selection of proprietary brands. A pioneer in ophthalmology, OCuSOFT^® introduced the first eyelid cleanser, the first topical anesthetic gel, the first “leave-on” antibacterial eyelid cleaner, the first supplement to enhance botulinum toxin injections and the first fourth generation preservative-free ophthalmic emulsion eye drop. Today, the company is most recognized for its #1 Doctor Recommended Brand of Eyelid Cleansers, OCuSOFT^® Lid Scrub^®, in addition to its standing as the preferred distributor of ophthalmic products and supplies by eye care professionals. For more information, please call 800-233-5469 or visit www.ocusoft.com.

¹Ousler III, George, et al. "An evaluation of Retaine ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye." Clinical Ophthalmology 9 (2015): 235-43. Web. 5 Feb. 2015.

Contact: Courtney Ahrens, Director of Marketing

Phone: 800-233-5469

Email: cahrens@ocusoft.com